New Delhi, May 4, 2026: Shares of Dr Lal PathLabs surged sharply on Monday, rising as much as 20% during intraday trade, as strong investor buying and high trading volumes lifted sentiment following the company’s Q4FY26 results.
The stock hit an intraday high of ₹1,640, while it was trading around ₹1,573 (up 15%) in the afternoon session, compared to the previous close of ₹1,367.20 on the NSE.
What Triggered the Rally?
The rally was largely driven by robust volume growth in core operations, even as profitability saw some pressure. Investors appeared to focus on the company’s revenue momentum and long-term growth prospects.
Trading activity remained elevated, with volumes crossing 7.9 million shares across exchanges, indicating strong institutional and retail participation.
Q4FY26 Results: Revenue Up, Profit Down
Despite the surge in stock price, the company reported a mixed set of quarterly numbers:
- Net profit declined ~15% to ₹132 crore, compared to ₹155 crore in the same quarter last year
- Revenue from operations grew 16% to ₹702 crore, up from ₹602 crore YoY
- Earnings per share (EPS) fell to ₹7.86 from ₹9.29
The strong topline performance was supported by higher patient volumes and improved test mix, which offset concerns around profitability.
Technical Indicators Signal Volatility
On the technical front, the stock briefly entered overbought territory, with its 14-day Relative Strength Index (RSI) crossing 70.
However, RSI later cooled to around 46, suggesting that the sharp rally witnessed some normalization during the session.
Dividend Announcement Adds Support
The company’s board has recommended a final dividend of ₹4 per share (40% on face value of ₹10) for FY26, subject to shareholder approval at the upcoming AGM.
- Record date: June 26, 2026
- Dividend payment will be made within 30 days after approval
This announcement further boosted investor confidence in the stock.
What Analysts Are Saying
Global brokerage Goldman Sachs highlighted that:
- Q4 sales beat expectations (10.5% YoY estimate)
- Strong growth was driven by higher patient volumes and better geographic mix
- EBITDA margin stood at 26.6%, broadly in line with expectations
Meanwhile, analysts at Nomura noted that:
- The stock is trading near seven-year low valuations
- Revenue growth exceeded estimates
- Margins are expected to improve to 27–28% going forward
They also expect revenue growth of 13–15% in the coming periods, supported by network expansion and infrastructure investments.
